The Mosaic Company — 5.1/10 — $23.36
Gate result: 2 of 3 gates FAIL (PARTIAL on oligopoly, NO on FCF, NO on management). Composite is capped at 5.5/10 by the gate framework. Actual composite of 5.10 sits below the cap, so no further adjustment is needed -- but the flag stands: Below Quality Bar -- Requires Exceptional Catalyst. MOS is structurally a worse business than NTR (composite 6.95) and management has not demonstrated execution at the level the contrarian thesis requires.
| Dimension | Score | Weight | Weighted |
|---|---|---|---|
| Financial Trends | 4 | 25% | 1.00 |
| Thematic Exposure | 6 | 25% | 1.50 |
| Management Quality | 4 | 20% | 0.80 |
| Investor Sentiment (Inverted) | 7 | 15% | 1.05 |
| Concerns, Catalysts & Risks | 5 | 15% | 0.75 |
| Composite | 100% | 5.10 |
The Mosaic Company is the world's largest combined producer of phosphate and potash crop nutrients, and the #1 fertilizer distributor in Brazil. The business runs through three segments: Mosaic Fertilizantes Brazil distribution (~40% revenue), Phosphate (~38% revenue, ~6-8% global share), and Potash (~22% revenue, ~10-13% global share, top-3 producer).
The contrarian setup rests on three pillars: (1) Insider cluster buying -- CEO Bodine, CFO Pires, and CAO all bought open-market on March 4, 2026 at $26.02, totaling ~$5M. They are underwater at today's $23.36, signaling real conviction at higher prices. (2) Catalyst stack -- China DAP export ban extended through August 2026, Canpotex sold out through June 2026, sulfur shock from Hormuz/Iran is exogenous and likely temporary, US asset reliability investments finally bearing fruit (3 of 4 plants at target rates Q1 2026). (3) Trough multiple on trough earnings -- 5.1x EV/EBITDA vs peer average 7.0x and NTR at 8.1x.
The quality concerns are equally real. 2 of 3 quality gates fail. Free cash flow has been negative in 3 of the last 4 quarters (Q3-25 -$135M, Q4-25 -$535M, Q1-26 -$253M), and long-term debt has grown 27% YoY while revenue grew only 8.4%. Management's 3-year guidance hit rate is ~36% -- FY25 phosphate production missed initial guide by 15-18%, Investor Day cost targets missed on both phosphate and potash, buybacks deferred twice, dividend frozen at $0.22/qtr. Q1 2026 adj EPS collapsed to $0.05 (down ~90% YoY) on the sulfur shock plus forced production curtailments -- a fragility that better-managed peers like NTR and CF absorbed.
Bottom line versus NTR. NTR (composite 6.95) is the higher-quality way to own the same agricultural intensification / food security theme. NTR has a wider potash moat (~20-25% global share vs MOS ~10-13%), generates positive FCF, has a vertically integrated retail business, and a much stronger management track record. MOS only earns its place on the watchlist because the asymmetry is real -- but it requires an exceptional catalyst (sulfur normalization + China export policy + US phosphate reliability all confirming) to work.
| Price (USD) | $23.36 | FY2025 Revenue | $12.05B (+8.4% YoY) |
| Market Cap | ~$7.42B | FY2025 Adj. EBITDA | $2.42B (+10% YoY) |
| EV/EBITDA (FY26E) | ~5.1x | Free Cash Flow (LTM) | Negative 3 of 4 qtrs |
| Q1 2026 Adj. EPS | $0.05 (-90% YoY) | Long-Term Debt | $4.29B (+27% YoY) |
| 52-Week Range | ~$23 - $38 (-33% from high) | Short Interest | ~22% (crowded short) |
| CEO | Bruce Bodine (since Aug 2023) | Insider Cluster Buy (Mar 2026) | ~$5M at $26.02 |
Mosaic receives a composite score of 5.10/10, capped by the quality gate framework (2 of 3 gates fail). The score reflects a genuine contrarian setup -- inverted sentiment (7) with insider cluster buying, decent thematic positioning (6), and trough valuation (5) -- offset by weak financials (4) and weak management execution (4). Fair value range is $23-27 and the current $23.36 sits at the low end of the base case.
Bull case (~$32-38, +37% to +63%): Sulfur prices normalize as Hormuz tensions ease; China DAP export restrictions extend further into 2026; US phosphate plants sustain target operating rates (Riverview 1.6Mt run-rate confirmed); Mosaic Biosciences doubles as guided; Mosaic Fertilizantes Brazil margin recovers post-impairments. Adj EBITDA rebuilds to $2.8-3.2B, FCF turns convincingly positive, multiple re-rates to 6.5-7.0x EV/EBITDA. Insiders are vindicated.
Base case (~$23-27, flat to +16%): Sulfur stays elevated longer than expected; phosphate margin recovery is choppy; Brazil stabilizes but doesn't bounce; potash holds at current levels with Belarus overhang. Adj EBITDA $2.3-2.5B; FCF marginally positive. Stock range-bound around fair value as the market waits for proof of execution. Total return: dividend (~3.8%) plus modest multiple drift.
Bear case (~$15-19, -19% to -36%): Belarus sanctions removal floods potash; sulfur stays at $1,200/t marginal cost through 2026; Brazil contraction continues with further Araxa-style write-downs; debt continues to climb forcing dividend cut or equity issuance; phosphogypsum stack environmental liability crystallizes. Adj EBITDA collapses to $1.6-1.8B; multiple compresses to 4.5x; stock retests low-teens. Insiders' $26 conviction proves expensive.
Bottom line: MOS is a watchlist contrarian setup, not a high-conviction buy. The asymmetry is real -- 5.1x trough multiple, $5M insider cluster buy at higher prices, identifiable catalyst stack -- but the quality gates fail for good reason. NTR (composite 6.95) is the structurally superior way to own the same theme, and absent a meaningful sulfur-normalization or China-export catalyst, MOS does not earn capital. Best monitored, not owned, until proof points emerge.
Key catalysts and monitoring points:
- Sulfur price trajectory: Currently at marginal $1,200/t after Hormuz / Iran disruption. Single most important variable -- a $200/t move impacts phosphate EBITDA by hundreds of millions. Watch shipping data, Iranian sulfur exports, and Persian Gulf risk premium.
- China DAP export policy (August 2026 review): Current export ban extension is the single biggest tailwind for global phosphate prices. Renewal would validate management's structural-tightness thesis; relaxation would crater the bull case.
- US phosphate operating rates: 3 of 4 plants reportedly at target rates Q1 2026 with Riverview at 1.6Mt run-rate. Need to see this sustained for 2-3 quarters before crediting management's reliability narrative.
- FCF inflection: Track quarterly FCF for evidence the trend is reversing. Two consecutive quarters of meaningfully positive FCF would meaningfully change the quality gate result.
- Belarus / Uralkali potash supply: Sanctions were lifted in March 2026. Watch for export ramp data -- a flood of Belarusian potash would crash MOP pricing and undermine the one segment that is genuinely working.
- Mosaic Fertilizantes Brazil: Q2-Q4 2026 segment EBITDA recovery from the Q1 -$422M operating loss. Further write-downs would signal deeper structural problems beyond Araxa.
- Insider activity: Any incremental open-market buying near current levels would strengthen the thesis; insider selling would be a major red flag given how recently they bought at $26.02.
- Capital return resumption: Buyback restart or dividend increase would signal management believes the FCF trough is past. Continued capital return pause confirms stress.
For the full analysis, see the Business Model, Financials, Thematics, Management, Valuation, and Sentiment pages.